Header Logo

Connection

JED NUCHTERN to Neuroblastoma

Back to Details
This is a "connection" page, showing publications JED NUCHTERN has written about Neuroblastoma.
JED NUCHTERN
Connection Strength
6.740
Neuroblastoma
  1. Long-Term Outcome of Young Infants With Suspected Neuroblastoma following Observation as Primary Therapy: A Report From the Children's Oncology Group. Pediatr Blood Cancer. 2025 Aug; 72(8):e31829.
    View in: PubMed
    Score: 0.616
  2. A subset of image-defined risk factors predict completeness of resection in children with high-risk neuroblastoma: An international multicenter study. Pediatr Blood Cancer. 2024 Oct; 71(10):e31218.
    View in: PubMed
    Score: 0.581
  3. Inhibition of Ubiquitin-Specific Protease 14 Suppresses Cell Proliferation and Synergizes with Chemotherapeutic Agents in Neuroblastoma. Mol Cancer Ther. 2019 06; 18(6):1045-1056.
    View in: PubMed
    Score: 0.402
  4. Wip1 inhibitor GSK2830371 inhibits neuroblastoma growth by inducing Chk2/p53-mediated apoptosis. Sci Rep. 2016 12 19; 6:38011.
    View in: PubMed
    Score: 0.343
  5. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma. Oncotarget. 2016 Dec 13; 7(50):82757-82769.
    View in: PubMed
    Score: 0.343
  6. Recent biologic and genetic advances in neuroblastoma: Implications for diagnostic, risk stratification, and treatment strategies. Semin Pediatr Surg. 2016 Oct; 25(5):257-264.
    View in: PubMed
    Score: 0.338
  7. Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study. J Clin Oncol. 2016 Mar 01; 34(7):740-6.
    View in: PubMed
    Score: 0.321
  8. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study. Ann Surg. 2012 Oct; 256(4):573-80.
    View in: PubMed
    Score: 0.256
  9. Neuroblastoma-derived secretory protein is a novel secreted factor overexpressed in neuroblastoma. Mol Cancer Ther. 2009 Aug; 8(8):2478-89.
    View in: PubMed
    Score: 0.206
  10. Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma. Mol Cancer Ther. 2009 Aug; 8(8):2461-9.
    View in: PubMed
    Score: 0.206
  11. Neuroblastoma-derived secretory protein messenger RNA levels correlate with high-risk neuroblastoma. J Pediatr Surg. 2007 Jan; 42(1):148-52.
    View in: PubMed
    Score: 0.172
  12. Perinatal neuroblastoma. Semin Pediatr Surg. 2006 Feb; 15(1):10-6.
    View in: PubMed
    Score: 0.161
  13. Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children's Oncology Group. Clin Cancer Res. 2026 Jan 06; 32(1):127-134.
    View in: PubMed
    Score: 0.161
  14. CXCR4 expression in neuroblastoma primary tumors is associated with clinical presentation of bone and bone marrow metastases. J Pediatr Surg. 2004 Oct; 39(10):1506-11.
    View in: PubMed
    Score: 0.147
  15. Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. J Pediatr Surg. 2025 Jan; 60(1):161896.
    View in: PubMed
    Score: 0.146
  16. Critical elements of pediatric neuroblastoma surgery. Semin Pediatr Surg. 2023 Oct; 32(5):151338.
    View in: PubMed
    Score: 0.139
  17. A Novel Standard for Systematic Reporting of Neuroblastoma Surgery: The International Neuroblastoma Surgical Report Form (INSRF): A Joint Initiative by the Pediatric Oncological Cooperative Groups SIOPEN*, COG**, and GPOH***. Ann Surg. 2022 03 01; 275(3):e575-e585.
    View in: PubMed
    Score: 0.123
  18. Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma. Cancer Res. 2002 Feb 15; 62(4):1123-8.
    View in: PubMed
    Score: 0.123
  19. Thoracoscopic Resection of Thoracic Inlet Neuroblastic Tumors in Young Children. J Laparoendosc Adv Surg Tech A. 2021 Dec; 31(12):1475-1479.
    View in: PubMed
    Score: 0.120
  20. Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. J Clin Oncol. 2021 10 10; 39(29):3229-3241.
    View in: PubMed
    Score: 0.118
  21. Characteristics of benign neuroblastic tumors: Is surgery always necessary? J Pediatr Surg. 2022 Aug; 57(8):1538-1543.
    View in: PubMed
    Score: 0.117
  22. Major histocompatibility complex-restricted lysis of neuroblastoma cells by autologous cytotoxic T lymphocytes. J Immunother. 2001 Jul-Aug; 24(4):305-11.
    View in: PubMed
    Score: 0.117
  23. Management of Neuroblastoma in Pediatric Patients. Surg Oncol Clin N Am. 2021 04; 30(2):291-304.
    View in: PubMed
    Score: 0.114
  24. Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors. Pediatr Blood Cancer. 2020 10; 67(10):e28417.
    View in: PubMed
    Score: 0.110
  25. Lysis of MYCN-amplified neuroblastoma cells by MYCN peptide-specific cytotoxic T lymphocytes. Cancer Res. 2000 Apr 01; 60(7):1908-13.
    View in: PubMed
    Score: 0.108
  26. Evolving biopsy techniques for the diagnosis of neuroblastoma in children. J Pediatr Surg. 2018 Nov; 53(11):2235-2239.
    View in: PubMed
    Score: 0.094
  27. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017 Aug 01; 35(22):2580-2587.
    View in: PubMed
    Score: 0.088
  28. Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling. Oncotarget. 2017 Jan 03; 8(1):1469-1480.
    View in: PubMed
    Score: 0.086
  29. The optimal timing of surgical resection in high-risk neuroblastoma. J Pediatr Surg. 2016 Oct; 51(10):1665-9.
    View in: PubMed
    Score: 0.083
  30. mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling. Apoptosis. 2015 Jan; 20(1):50-62.
    View in: PubMed
    Score: 0.075
  31. Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma. Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):858-62.
    View in: PubMed
    Score: 0.073
  32. A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways. Cell Death Dis. 2014 Feb 20; 5:e1079.
    View in: PubMed
    Score: 0.070
  33. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis. Cell Death Dis. 2013 Oct 17; 4:e867.
    View in: PubMed
    Score: 0.069
  34. TAK1 inhibitor 5Z-7-oxozeaenol sensitizes neuroblastoma to chemotherapy. Apoptosis. 2013 Oct; 18(10):1224-34.
    View in: PubMed
    Score: 0.069
  35. Needle core vs open biopsy for diagnosis of intermediate- and high-risk neuroblastoma in children. J Pediatr Surg. 2012 Jun; 47(6):1261-6.
    View in: PubMed
    Score: 0.063
  36. Dual-specificity phosphatase 26 is a novel p53 phosphatase and inhibits p53 tumor suppressor functions in human neuroblastoma. Oncogene. 2010 Sep 02; 29(35):4938-46.
    View in: PubMed
    Score: 0.055
  37. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009 Jan 10; 27(2):298-303.
    View in: PubMed
    Score: 0.049
  38. Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma. Clin Cancer Res. 2008 Nov 01; 14(21):7028-34.
    View in: PubMed
    Score: 0.049
  39. The role of bone marrow evaluation in the staging of patients with otherwise localized, low-risk neuroblastoma. Pediatr Blood Cancer. 2005 Dec; 45(7):916-9.
    View in: PubMed
    Score: 0.040
  40. Gene profiling of high risk neuroblastoma. World J Surg. 2005 Mar; 29(3):317-24.
    View in: PubMed
    Score: 0.038
  41. Cyclin D and cisplatin cytotoxicity in primary neuroblastoma cell lines. Anticancer Drugs. 2004 Oct; 15(9):883-8.
    View in: PubMed
    Score: 0.037
  42. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer. 2001 Oct 15; 94(2):228-36.
    View in: PubMed
    Score: 0.030
  43. Selection of human antitumor single-chain Fv antibodies from the B-cell repertoire of patients immunized against autologous neuroblastoma. Med Pediatr Oncol. 2000 Dec; 35(6):692-5.
    View in: PubMed
    Score: 0.028
  44. Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. Hum Gene Ther. 2000 Jul 01; 11(10):1477-88.
    View in: PubMed
    Score: 0.027
  45. Infradiaphragmatic extralobar pulmonary sequestration masquerading as an intra-abdominal, suprarenal mass. Pediatr Surg Int. 1997 Sep; 12(7):529-31.
    View in: PubMed
    Score: 0.022
  46. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A. 2004 Sep 28; 101(39):14228-33.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.